Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
:GSK
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.72 - $44.67
Previous CloseN/A
Volume981.79K
Average Volume (3M)5.51M
Market Cap
$75.28B
Enterprise Value$97.13B
Total Cash (Recent Filing)$3.62B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)17.2
Beta0.30
Next Earnings
Oct 29, 2025EPS Estimate
1.24Next Dividend Ex-Date
Aug 15, 2025Dividend Yield4.27%
Share Statistics
EPS (TTM)1.24
Shares Outstanding2,038,674,300
10 Day Avg. Volume5,849,844
30 Day Avg. Volume5,509,356
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue3.07
Enterprise Value/Gross Profit4.30
Enterprise Value/Ebitda11.28
Forecast
1Y Price Target
$41.00Price Target Upside9.86% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of efimosfermin expands GSK's hepatology portfolio and aligns with their business development strategy.
Product DevelopmentGSK's ongoing development of GSK4532990 in MASH and the potential commercial synergies with their emerging liver portfolio could enhance their R&D capabilities.
Bears Say
Manufacturing ComplexityThe complicated manufacturing process for Trelegy could pose challenges despite suggesting a potential competitive advantage.
GlaxoSmithKline News
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was $31.71 and its highest was $44.67 in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is $75.28B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 29, 2025 which is in 82 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jul 30, 2025. The company reported $1.236 earnings per share for the quarter, beating the consensus estimate of $1.171 by $0.065.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of $0.421 which represents an annual dividend yield of 4.27%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 1.24.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 2,038,674,300 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of $1.236 in its last earnings report, beating expectations of $1.171. Following the earnings report the stock price went up 3.451%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GSK
GlaxoSmithKline Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$41.00 (9.86% Upside)
$41.00 (9.86% Upside)
Blogger Sentiment
Bullish
GSK Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 19.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.89%
12-Months-Change
Fundamentals
Return on Equity
23.04%
Trailing 12-Months
Asset Growth
10.63%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
GSK Company Deck
GSK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
GSK's Q2 2025 results reflect strong financial performance driven by Specialty Medicines and vaccines, significant R&D progress, and robust cash generation. However, challenges remain in the form of supply chain costs, market difficulties in China, and delayed product launches.View all GSK earnings summariesGSK Stock 12 Month Forecast
Average Price Target
$41.00
▲(9.86% Upside)
Technical Analysis
Ownership Overview
―
Insiders
6.48% Mutual Funds
0.33% Other Institutional Investors
92.98% Public Companies and
Individual Investors